
    
      Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified
      below:

      Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated
      liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)
    
  